Quarterly ResultMay 11, 2026, 04:07 PM
Sana Biotechnology Partners with Mayo Clinic, Reports Positive Clinical Data
AI Summary
Sana Biotechnology announced a strategic collaboration with Mayo Clinic to accelerate the development of SC451 for type 1 diabetes, which includes a $25.0 million equity investment from Mayo Clinic. The company also reported positive 14-month clinical results for UP421 in a type 1 diabetes patient, demonstrating ongoing survival and function without immunosuppression. For Q1 2026, Sana reported a net loss of $47.2 million and a cash position of $101.1 million, with an expected cash runway into 2027. Progress continues on SC451 and SG293 clinical trials, expected to start later this year, and SG227 by mid-2027.
Key Highlights
- Strategic collaboration with Mayo Clinic announced for SC451 development.
- Mayo Clinic made an approximately $25.0 million equity investment in Sana.
- Positive 14-month clinical results for UP421 in type 1 diabetes patient.
- Q1 2026 net loss of $47.2 million, or $0.17 per share.
- Cash, cash equivalents, and marketable securities totaled $101.1 million.
- Expected cash runway into 2027, including Mayo Clinic investment.
- SC451 and SG293 Phase 1 trials expected to start later this year.
- Brian Piper appointed Executive Vice President, Chief Financial Officer.